Immunotherapy of cancer with genetically modified tumor vaccines

Research output: Contribution to journalReview article

74 Scopus citations

Abstract

Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy in the adjuvant setting of patients with low tumor volume would contribute to further reduction of the remaining tumor and establish long-lasting immunity that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-γ (IFNγ), or granulocyte-macrophage colony stimulating factor (GM-CSF), or costimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease. Moreover, in some instances, the cured animals have retained immunological memory, as indicated by the fact that animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor-bearing animals against nonimmunogenic or weakly immunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.

Original languageEnglish (US)
Pages (from-to)101-107
Number of pages7
JournalSeminars in Oncology
Volume23
Issue number1
StatePublished - Mar 14 1996
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this